<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication - Fontes, LES - 2019 | Cochrane Library</title> <meta content="N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication - Fontes, LES - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012357.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication - Fontes, LES - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012357.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012357.pub2" name="dc.identifier" scheme="DOI"/> <meta content="N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication" name="citation_title"/> <meta content="Luís Eduardo S Fontes" name="citation_author"/> <meta content="Petrópolis Medical School" name="citation_author_institution"/> <meta content="luis.fontes@ceo2.com.br" name="citation_author_email"/> <meta content="Ana Luiza C Martimbianco" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Carolina Zanin" name="citation_author"/> <meta content="Hospital Alcides Carneiro" name="citation_author_institution"/> <meta content="Rachel Riera" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD012357.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/02/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012357.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012357.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012357.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Helicobacter pylori; Acetylcysteine [adverse effects, *therapeutic use]; Anti‐Bacterial Agents [*therapeutic use]; Chemotherapy, Adjuvant [adverse effects, methods]; Helicobacter Infections [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012357.pub2&amp;doi=10.1002/14651858.CD012357.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012357\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012357\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ms","fr","zh_HANS","hr","fa","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012357.pub2",title:"N\\u2010acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication",firstPublishedDate:"Feb 12, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012357.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012357.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012357.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012357.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012357.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012357.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012357.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012357.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012357.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012357.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11972 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012357.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-sec-0132"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-sec-0078"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-sec-0126"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/appendices#CD012357-sec-0137"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/table_n/CD012357StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/table_n/CD012357StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information#CD012357-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Luís Eduardo S Fontes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information#CD012357-cr-0003">Ana Luiza C Martimbianco</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information#CD012357-cr-0004">Carolina Zanin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information#CD012357-cr-0005">Rachel Riera</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information/en#CD012357-sec-0145">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 February 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012357.pub2">https://doi.org/10.1002/14651858.CD012357.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012357-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012357-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012357-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012357-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012357-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012357-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012357-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012357-abs-0001" lang="en"> <section id="CD012357-sec-0001"> <h3 class="title" id="CD012357-sec-0001">Background</h3> <p><i>Helicobacter pylori</i> (<i>H pylori</i>) is one of the most common pathogens to establish and cause infection in human beings, affecting about 50% of the world's population. Prevalence may be as high as 83% in Latin American countries and as low as 17% in North America. Approximately 20% of infected people will manifest disease; people at high risk include those who live in low‐ and middle‐income countries with poor sanitary conditions, since the mechanism of transmission seems to be oral‐oral or faecal‐oral (mostly during infancy). There are several antibiotic regimens to treat the infection, but antibiotic resistance is growing around the world. New adjuvant drugs — such as probiotics, statins, curcumin, and N‐acetylcysteine (NAC) — are being tested to enhance eradication rates. </p> <p>N‐acetylcysteine can destabilise the biofilm structure; it also has synergic action with antibiotics, and bactericidal effects. In addition, NAC has antioxidant properties, and has a primary mucolytic effect by reducing the thickness of the gastric mucus layer, both of which may exert beneficial adjuvant effects on <i>H pylori</i> eradication. </p> </section> <section id="CD012357-sec-0002"> <h3 class="title" id="CD012357-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of N‐acetylcysteine as an adjuvant therapy to antibiotics for <i>Helicobacter pylori</i> eradication. </p> </section> <section id="CD012357-sec-0003"> <h3 class="title" id="CD012357-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 to April 2018), Embase (1988 to April 2018), CINAHL (1982 to April 2018), LILACS (1982 to April 2018), grey literature databases and trials registries. We handsearched the reference lists of relevant studies. We screened 726 articles and assessed 18 for eligibility. </p> </section> <section id="CD012357-sec-0004"> <h3 class="title" id="CD012357-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of any antibiotic regimen plus NAC, in adults infected with <i>H pylori</i>. To be included, trials had to use a control consisting of the same antibiotic regimen with or without placebo. Outcomes of interest were eradication rates, and gastrointestinal, toxic, and allergic adverse events. Reporting of the primary outcomes listed here was not an inclusion criterion for the review. </p> </section> <section id="CD012357-sec-0005"> <h3 class="title" id="CD012357-sec-0005">Data collection and analysis</h3> <p>Two review authors independently reviewed and extracted data and completed the 'Risk of bias' assessments. A third review author independently confirmed the 'Risk of bias' assessments. We used Review Manager 5 software for data analysis. We contacted study authors if there was missing information. </p> </section> <section id="CD012357-sec-0006"> <h3 class="title" id="CD012357-sec-0006">Main results</h3> <p>We included eight RCTs (with a total of 559 participants) in this review. The studies recruited outpatients aged between 17 and 76 years who were referred to endoscopy centres in several different countries. The certainty of evidence was reduced for most outcomes due to the poor methodological quality of included studies; issues mainly related to the generation of allocation sequence, allocation concealment, and blinding (this last domain related specifically to adverse outcomes). </p> <p>We are uncertain whether the addition of NAC to antibiotics improves <i>H pylori</i> eradication rates, compared with the addition of placebo or no NAC (38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low‐certainty evidence). A post‐hoc sensitivity analysis, in which we removed studies that tested antibiotic regimens no longer recommended in clinical practice, showed that the addition of NAC may improve eradication rates compared to control (27.2% versus 37.6%, RR 0.71, 95% CI 0.53 to 0.94; participants = 397; published studies = five). </p> <p>We are uncertain whether NAC is associated with a higher risk of gastrointestinal adverse events compared to control (23.9% versus 18.9%, RR 1.25, 95% CI 0.85 to 1.85; participants = 336; studies = five; very low‐certaintyevidence), or allergic adverse events (2% versus 0%, RR 2.98, 95% CI 0.32 to 27.74; participants = 336; studies = five; very low‐certainty evidence). There were no reports of toxic adverse events amongst included studies. </p> </section> <section id="CD012357-sec-0007"> <h3 class="title" id="CD012357-sec-0007">Authors' conclusions</h3> <p>We are uncertain whether the addition of NAC to antibiotics improves <i>H pylori</i> eradication rates compared with the addition of placebo or no NAC. Due to the clinical, statistical and methodological heterogeneity found in included studies, and the uncertainty observed when analysing therapy subgroups, any possible beneficial effect of NAC should be regarded cautiously. </p> <p>We are uncertain whether NAC is associated with a higher risk of gastrointestinal or allergic adverse events compared with placebo or no NAC. There were no reports of toxic adverse events amongst the included studies. </p> <p>Further large, well‐designed, randomised clinical studies should be conducted, with good reporting standards and appropriate collection of efficacy and safety outcomes, especially for current recommended antibiotic regimens. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012357-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012357-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012357-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012357-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012357-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012357-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012357-abs-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012357-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012357-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012357-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012357-abs-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012357-abs-0017">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012357-abs-0005" lang="en"> <h3>N‐acetylcysteine taken with antibiotics for treatment of Helicobacter pylori infection</h3> <p><b>Review question</b> </p> <p>Is the addition of N‐acetylcysteine to antibiotics safe and does it improve cure rates for <i>Helicobacter pylori</i> infection? </p> <p><b>Background</b> </p> <p><i>Helicobacter pylori</i> (<i>H pylori</i>) is a bacteria that lives in the stomach and might cause several diseases such as gastric cancer, ulcer disease, and others. Colonisation occurs in about one‐half of the world's population and is more common in countries with poor sanitary conditions. People become infected by consuming contaminated water. </p> <p>The infection is treated using antibiotics and a drug which reduces acid production in the stomach. However, rates of antibiotic resistance are rising around the world, which is reducing the cure rates even with treatment. New medications are being tested to improve cure rates. One of these medications is N‐acetylcysteine (NAC). NAC is a drug that helps to dissolve mucus in respiratory diseases. It can be taken by mouth (orally) or injected into a vein (intravenous). NAC can destroy some mechanisms of survival of <i>H pylori</i> and could improve cure rates. </p> <p><b>Study characteristics</b> </p> <p>We included eight studies (specifically, randomised controlled trials (RCTs)) with a total of 559 people aged between 17 and 76 years old. The evidence is current to April 2018. All studies recruited outpatients from endoscopy centres (centres that specialise in an examination done with a flexible tube with a camera that is inserted into stomach) in several countries. The antibiotic combinations tested were very different in the included studies, as were the doses of NAC (600 mg to 1800 mg per day). NAC was compared with placebo (dummy pill) or nothing. </p> <p><b>Key results</b> </p> <p>We are uncertain whether the addition of NAC to antibiotics improves <i>H pylori</i> cure rates compared with the addition of placebo or no NAC. Any possible beneficial effect of NAC should be regarded cautiously because the included studies were very different and of low certainty, with some flaws that could have compromised their results and consequently, the results of this review. </p> <p>We are uncertain whether NAC is associated with a higher risk of gastrointestinal or allergic adverse events compared with placebo or no NAC. There were no reports of toxic adverse events amongst the included studies. </p> <p>Further large, well‐designed randomised clinical studies, with good reporting standards and appropriate collection of effectiveness and safety outcomes should be done, especially for current recommended antibiotic combinations. </p> <p><b>Quality of the evidence</b> </p> <p>The overall certainty of the evidence for eradication rates ranged from very low to low. Five studies provided information on adverse events (side effects), and the certainy of evidence was very low. The included studies were poorly conducted and this reduced our confidence in the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012357-sec-0132" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012357-sec-0132">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012357-sec-0193">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012357-sec-0132"></div> <h3 class="title" id="CD012357-sec-0133">Implications for practice</h3> <section id="CD012357-sec-0133"> <p>The rate of development of new antibiotic drugs has been declining in the last few years (<a href="./references#CD012357-bbs2-0027" title="FairRJ , TorY . Antibiotics and bacterial resistance in the 21st century. Perspectives in medicinal chemistry2014;6:25‐64. [PUBMED: 25232278] ">Fair 2014</a>). Clinicians and those infected are exposed to rising rates of resistance to antibiotics. Therefore, new regimens and associations of drugs are currently being tested for <i>H pylori</i> infection. The recently published Maastricht V/Florence Consensus Report on the management of <i>H pylori</i> has changed the recommendation about who should be treated; the guideline advises that all people with confirmed infection should receive treatment, regardless of having gastric abnormalities (<a href="./references#CD012357-bbs2-0044" title="MalfertheinerP , MegraudF , O'MorainCA , GisbertJP , KuipersEJ , AxonAT , et al. Management of Helicobacter pylori infection‐the Maastricht V/Florence Consensus Report. Gut2017;66(1):6‐30. [PUBMED: 27707777] ">Malfertheiner 2017</a>). More people will have to be treated, and as a result, antibiotic resistance should increase with this practice. </p> <p>We are uncertain whether the addition of NAC to antibiotics improves <i>H pylori</i> eradication rates compared with the addition of placebo or no NAC. Due to the clinical, statistical and methodological heterogeneity found in the studies included in this review, and the uncertainty observed when analysing therapy subgroups, any possible beneficial effect of NAC should be regarded cautiously. Furthermore, we are uncertain if there are differences in eradication rates between smokers and non‐smokers who take NAC added to the antibiotic regimen. </p> <p>We are uncertain whether the addition of NAC is associated with higher risk of adverse events (gastrointestinal or allergic) compared with the addition of placebo or no NAC. There were no reports of toxic adverse events amongst included studies. </p> </section> <h3 class="title" id="CD012357-sec-0134">Implications for research</h3> <section id="CD012357-sec-0134"> <p>Due to the lack of available data and low quality of the current evidence, as well as the uncertainty observed in subgroup analysis, future research still needs to answer the following questions. </p> <p> <ul id="CD012357-list-0023"> <li> <p>Is NAC addition effective and safe for<i>H pylori</i> eradication in currently recommended antibiotic regimens? </p> </li> <li> <p>What is the optimal dose of NAC?</p> </li> <li> <p>Is NAC effective for both newly and previously treated people?</p> </li> </ul> </p> <p>Further large, well‐designed randomised clinical studies, with good reporting standards and appropriate collection of efficacy and safety outcomes, should be done. A particular focus for investigation should be currently recommended antibiotic regimens, such as standard clarithromycin triple therapies, bismuth‐based therapies, and quinolone‐based therapies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012357-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012357-sec-0043"></div> <div class="table" id="CD012357-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any antibiotic regimen plus N‐acetylcysteine compared to the same regimen without N‐acetylcysteine (with or without placebo) for Helicobacter pylori infection</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any antibiotic regimen plus NAC compared to the same regimen without NAC (with or without placebo) for <i>H pylori</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with<i>H pylori</i> infection<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> any antibiotic regimen plus NAC<br/> <b>Comparison:</b> the same antibiotic regimen (with or without placebo) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any antibiotic regimen without NAC</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any antibiotic regimen plus NAC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Eradication rate</b> </p> <p>Follow‐up: 38 to 175 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.74</b><br/> (0.51 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>559<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>491 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b><br/> (250 to 530) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Triple therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>483 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> <p>(203 to 440)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62</p> <p>(0.42 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Dual therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>702 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000</p> <p>(295 to 632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62</p> <p>(0.42 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Sequential therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>328 per 1000</p> <p>(193 to 546)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78</p> <p>(0.46 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Bismuth quadruple therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> <p>(84 to 383)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98</p> <p>(0.46 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>No PPI, antibiotic monotherapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>456 per 1000</p> <p>(264 to 788)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14</p> <p>(0.66 to 1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Gastrointestinal adverse events</b> </p> <p>Follow‐up: 38 to 175 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.25</b><br/> (0.85 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>336<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>189 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b><br/> (161 to 350) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Triple therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>399 per 1000</p> <p>(171 to 942)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.33</p> <p>(0.57 to 3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(1RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Dual therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Sequential therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000</p> <p>(131 to 550)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02</p> <p>(0.50 to 2.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Bismuth quadruple therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>345 per 1000</p> <p>(198 to 603)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.38</p> <p>(0.79 to 2.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>No PPI, antibiotic monotherapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Allergic adverse events</b> </p> <p>Follow‐up: 38 to 175 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.98</b><br/> (0.32 to 27.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>336<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Triple therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Dual therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00</p> <p>(0.13 to 68.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Sequential therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in either group</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Bismuth quadruple therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.95</p> <p>(0.12 to 71.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>No PPI, antibiotic monotherapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Toxic adverse events</b> </p> <p>Follow‐up: 38 to 175 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>336<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events in either group</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Triple therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Dual Therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Sequential therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Bismuth quadruple therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>No PPI, antibiotic monotherapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>PPI:</b> proton pump inhibitor; <b>NAC:</b> N‐acetylcysteine; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> We downgraded by one level due to risk of bias (lack of information on sequence generation and allocation concealment). </p> <p><sup>2</sup> We downgraded by one level due to imprecision (the confidence interval includes both null effect and appreciable benefit (RR 0.75)). </p> <p><sup>3</sup> We downgraded by two levels due to inconsistency (large variation of effect, confidence intervals do not overlap, I<sup>2</sup> &gt; 50% and P &lt; 0.05). </p> <p><sup>4</sup> We downgraded by two levels due to risk of bias (lack of blinding of participants, personnel, and outcome assessors). </p> <p><sup>5</sup> We downgraded by two levels due to imprecision (wide confidence interval that includes appreciable harm (RR 1.25)). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012357-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012357-sec-0044">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012357-sec-0153">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012357-sec-0044"></div> <section id="CD012357-sec-0045"> <h3 class="title" id="CD012357-sec-0045">Description of the condition</h3> <p>Since 1875, several scientists have observed that gastric tissue specimens and gastric aspirates contained bacteria (<a href="./references#CD012357-bbs2-0013" title="BlaserMJ . An endangered species in the stomach. Scientific American2005;292(2):38‐45. [PUBMED: 15715390] ">Blaser 2005</a>). However, it was only in 1982 that two Australian physicians isolated a gram‐negative microaerophilic spiral bacterium from gastric specimens which appeared initially to be of the <i>Campylobacter</i> genus (<a href="./references#CD012357-bbs2-0045" title="MarshallBJ , WarrenJR . Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet1984;1(8390):1311‐5. [PUBMED: 6145023] ">Marshall 1984</a>), and that were supposed to be associated with gastritis. Some years later, observations of the bacterial structure demonstrated that they did not fulfil some characteristics of the <i>Campylobacter</i> genus. A new species was created, entitled <i>Helicobacter</i> , and later the micro‐organism was named <i>H pylori</i>. </p> <p><i>H pylori</i> is one of the most successful pathogens to establish and cause infection in human beings, after only <i>Streptococcus mutans</i> (<i>S mutans</i>) (<a href="./references#CD012357-bbs2-0017" title="CammarotaG , SanguinettiM , GalloA , PosteraroB . Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Alimentary pharmacology &amp; therapeutics2012;36(3):222‐30. [PUBMED: 22650647] ">Cammarota 2012</a>). Colonisation occurs in 50% of the adult population (<a href="./references#CD012357-bbs2-0037" title="HuntRH , XiaoSD , MegraudF , Leon‐BaruaR , BazzoliF , van derMerweS , et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. Journal of Gastrointestinal and Liver Diseases2011;20(3):299‐304. [PUBMED: 21961099] ">Hunt 2011</a>), with a wide variation in prevalence according to the region studied. Prevalence may be as high as 83% in Latin American countries and as low as 17% in North America (<a href="./references#CD012357-bbs2-0015" title="CalvetX , Ramirez LazaroMJ , LehoursP , MegraudF . Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter2013;18 Suppl 1:5‐11. [PUBMED: 24011238] ">Calvet 2013</a>). Approximately 20% of infected people will manifest disease (<a href="./references#CD012357-bbs2-0053" title="VeneritoM , KriegerT , EckerT , LeandroG , MalfertheinerP . Meta‐analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion2013;88(1):33‐45. [PUBMED: 23880479] ">Venerito 2013</a>). Those at high risk include people who live in low‐ and middle‐income countries with poor sanitary conditions, since the mechanism of transmission seems to be oral‐oral or faecal‐oral, mostly during infancy (<a href="./references#CD012357-bbs2-0023" title="DunnBE , CohenH , BlaserMJ . Helicobacter pylori . Clinical Microbiology Reviews1997;10(4):720‐41. [PUBMED: 9336670] ">Dunn 1997</a>). Strains of bacteria are present in faeces, saliva, gastric mucosa, and dental plaque, reinforcing the hypothesis of these routes of transmission (<a href="./references#CD012357-bbs2-0048" title="MomtazH , SouodN , DabiriH , SarsharM . Study of Helicobacter pylori genotype status in saliva, dental plaques, stool and gastric biopsy samples. World Journal of Gastroenterology2012;18(17):2105‐11. [PUBMED: 22563199] ">Momtaz 2012</a>). A positive result in the urea breath test, serology, stool antigen test, endoscopic biopsies with rapid urease reaction, histology or culture, confirms the diagnosis of <i>H pylori</i> infection. </p> <p>The micro‐organism acts by disrupting the mucosal layer of the stomach, adhering to epithelial cells and leading to chronic inflammation of gastric mucosa. Persistent inflammation leads to chronic gastritis, atrophy, intestinal metaplasia, dysplasia, and neoplasm (<a href="./references#CD012357-bbs2-0020" title="CorreaP . Human gastric carcinogenesis: a multistep and multifactorial process ‐ First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Research1992;52(24):6735‐40. [PUBMED: 1458460] ">Correa 1992</a>). Important virulence factors of <i>H pylori</i> contribute to successful colonisation and infection. These include: </p> <p> <ul id="CD012357-list-0001"> <li> <p>urease synthesis (to inactivate toxicity by gastric urea and to resist in acidic milieu);</p> </li> <li> <p>flagella, lipases, and proteases (to penetrate the intimacy of mucus);</p> </li> <li> <p>adhesins (to attach to epithelial cells and allow interaction);</p> </li> <li> <p>effector toxins (including cytotoxin‐associated gene A (CagA), vacuolating cytotoxin gene A (VacA), and others, which induce changes in epithelium cytoskeleton and secretion of interleukin 8 (IL‐8)) (<a href="./references#CD012357-bbs2-0039" title="KaoCY , SheuBS , WuJJ . Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomedical Journal2016;39(1):14‐23. [PUBMED: 27105595] ">Kao 2016</a>). </p> </li> </ul> </p> <p>Current data show that <i>H pylori</i> infection is associated with a range of gastric diseases (most as a result of chronic inflammation), including atrophic gastritis, mucosal‐associated lymphoid tissue (MALT) lymphoma, peptic ulcer disease, gastric cancer, and functional dyspepsia (<a href="./references#CD012357-bbs2-0041" title="KuipersEJ . Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Alimentary Pharmacology &amp; Therapeutics1997;11 Suppl 1:71‐88. [PUBMED: 9146793] ">Kuipers 1997</a>; <a href="./references#CD012357-bbs2-0042" title="MalfertheinerP , ChanFK , McCollKE . Peptic ulcer disease. Lancet2009;374(9699):1449‐61. [PUBMED: 19683340] ">Malfertheiner 2009</a>; <a href="./references#CD012357-bbs2-0056" title="ZhaoB , ZhaoJ , ChengWF , ShiWJ , LiuW , PanXL , et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta‐analysis of randomized controlled studies with 12‐month follow‐up. Journal of Clinical Gastroenterology2014;48(3):241‐7. [PUBMED: 24002127] ">Zhao 2014</a>). Some non‐gastric conditions are also associated with <i>H pylori</i> infection, such as idiopathic thrombocytopenic purpura (<a href="./references#CD012357-bbs2-0052" title="StasiR , SarpatwariA , SegalJB , OsbornJ , EvangelistaML , CooperN , et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood2009;113(6):1231‐40. [PUBMED: 18945961] ">Stasi 2009</a>), and idiopathic iron deficiency anaemia (<a href="./references#CD012357-bbs2-0019" title="ChaabaneNB , MansourIB , HellaraO , LoghmeriH , BdiouiF , SaferL , et al. Role of Helicobacter pylori infection in iron deficiency anemia [Role de l'infection par l'Helicobacter pylori dans l'anemie ferriprive]. Presse Medicale2011;40(3):239‐47. [PUBMED: 21196096] ">Chaabane 2011</a>). </p> <p>See <a href="./appendices#CD012357-sec-0138">Appendix 1</a> for a glossary of terms. </p> </section> <section id="CD012357-sec-0046"> <h3 class="title" id="CD012357-sec-0046">Description of the intervention</h3> <p>Several regimens of antibiotic treatment are available for <i>H pylori</i> eradication. Most of them are associated with a proton pump inhibitor (PPI) to enhance bioavailability and chemical properties of antibiotics and raise cure rates. Since the 1990s PPI‐clarithromycin triple therapy has become the first‐line treatment of <i>H pylori</i> infection. This regimen consists of a PPI plus clarithromycin plus amoxicillin or metronidazole. Only one decade later, the efficacy of such therapy declined, with clarithromycin resistance emerging as the most important cause. Other explanations for the decrease in eradication rates of PPI‐clarithromycin triple therapy are compliance, type of strains, high gastric acidity and high bacterial load. Eradication rates dropped from about 80% in the early 1990s to less than 70% a decade later (<a href="./references#CD012357-bbs2-0031" title="GrahamDY , FischbachL . Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut2010;59(8):1143‐53. [PUBMED: 20525969] ">Graham 2010</a>). </p> <p>In 2012, the European Helicobacter Study Group (EHSG) published the Maastricht IV/Florence Consensus Report (<a href="./references#CD012357-bbs2-0024" title="European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. GUT2012;61(5):302‐84. ">EHSG 2012</a>), proposing an approach based on local clarithromycin resistance patterns, assuming a threshold of 15% to 20% to separate regions with high and low clarithromycin resistance. Other antibiotic regimens using combinations of metronidazole, fluoroquinolones, tetracycline, and bismuth exhibit the same concerns about increasing resistance rates. If eradication was unsuccessful after an initial therapy (so‐called 'first‐line therapy'), people would need a second treatment with a different regimen. If this second‐line treatment failed, the third regimen would need to be guided by culture and antibiogram (<a href="./references#CD012357-bbs2-0043" title="MalfertheinerP , MegraudF , O'MorainCA , AthertonJ , AxonAT , BazzoliF , et al. Management of Helicobacter pylori infection — the Maastricht IV/ Florence Consensus Report. Gut2012;61(5):646‐64. [PUBMED: 22491499] ">Malfertheiner 2012</a>). </p> <p>New approaches are being tested to enhance <i>H pylori</i> eradication rates, such as probiotics, statins, curcumin, and N‐acetylcysteine (NAC). </p> <p>NAC is a component of the amino acid L‐cysteine and is available in intravenous or oral preparations. After oral ingestion, it is almost entirely absorbed and metabolised by the small intestine and liver. Only a small concentration of intact NAC reaches the plasma and tissues (<a href="./references#CD012357-bbs2-0022" title="DeCaroL , GhizziA , CostaR , LongoA , VentrescaGP , LodolaE . Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittel‐Forschung1989;39(3):382‐6. [PUBMED: 2757663] ">De Caro 1989</a>). Peak plasma levels are observed after less than one hour; half‐life is about two hours and it is not detectable in plasma after 10 to 12 hours (<a href="./references#CD012357-bbs2-0014" title="BorgstromL , KagedalB , PaulsenO . Pharmacokinetics of N‐acetylcysteine in man. European Journal of Clinical Pharmacology1986;31(2):217‐22. [PUBMED: 3803419] ">Borgstrom 1986</a>). NAC may be administered orally or intravenously, and it seems to have a good safety profile at dosages of 1200 mg twice daily or lower. Severe adverse effects are rare and include gastrointestinal, cutaneous, and allergic effects (<a href="./references#CD012357-bbs2-0040" title="KellyGS . Clinical applications of N‐acetylcysteine. Alternative Medicine Review1998;3(2):114‐27. [PUBMED: 9577247] ">Kelly 1998</a>; <a href="./references#CD012357-bbs2-0046" title="MilleaPJ . N‐acetylcysteine: multiple clinical applications. American Family Physician2009;80(3):265‐9. [PUBMED: 19621836] ">Millea 2009</a>). </p> <p>N‐acetylcysteine metabolites stimulate glutathione synthesis, promoting detoxification and acting mainly as free oxygen radical scavengers. NAC promotes the cleavage of disulfide bonds of mucus glycoproteins, reducing viscosity and thickness of mucus, including the gastric mucus layer. Due to these properties, NAC has been used in several clinical situations, such as chronic obstructive pulmonary disease, influenza, idiopathic pulmonary fibrosis, polycystic ovary syndrome, prevention of contrast‐induced nephropathy, acetaminophen overdose, cancer, heart disease, and heavy metal toxicity (<a href="./references#CD012357-bbs2-0040" title="KellyGS . Clinical applications of N‐acetylcysteine. Alternative Medicine Review1998;3(2):114‐27. [PUBMED: 9577247] ">Kelly 1998</a>; <a href="./references#CD012357-bbs2-0046" title="MilleaPJ . N‐acetylcysteine: multiple clinical applications. American Family Physician2009;80(3):265‐9. [PUBMED: 19621836] ">Millea 2009</a>; <a href="./references#CD012357-bbs2-0051" title="SherwoodPV , WibawaJI , AthertonJC , JordanN , JenkinsD , BarrettDA , et al. Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats. Gut2002;51(4):490‐5. [PUBMED: 12235069] ">Sherwood 2002</a>). </p> <p>N‐acetylcysteine was first proposed as an adjuvant therapy for <i>H pylori</i> in a study by Zala and colleagues (<a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>); it demonstrated improved eradication rates in people randomised to receive antibiotics and NAC, compared with a control group that received only antibiotics. Following on from this, other studies demonstrated conflicting results. Some reported better eradication rates when NAC was associated with antibiotics (<a href="./references#CD012357-bbs2-0016" title="CammarotaG , BrancaG , ArditoF , SanguinettiM , IaniroG , CianciR , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. [PUBMED: 20478402] ">Cammarota 2010</a>; <a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>), and others reported no beneficial effect on eradication rates (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>; <a href="./references#CD012357-bbs2-0055" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐Line sequential therapy for Helicobacter pylori infection: a randomized controlled pilot trial. Gut and Liver2015;9:1‐6. [PUBMED: 26347514] ">Yoon 2015</a>). </p> </section> <section id="CD012357-sec-0047"> <h3 class="title" id="CD012357-sec-0047">How the intervention might work</h3> <p>Biofilms are complex biological systems produced by various species of bacteria. <i>H pylori</i> produce an extracellular polymeric matrix (polysaccharides, DNA, proteins and lipids) with water channels as a strategy to overcome environmental stress and protect itself. Colonies of <i>H pylori</i> can live embedded in biofilms in two primary forms: spiral or coccoid. Spiral forms are cultivable and virulent, while coccoid forms are viable but non‐cultivable, latent, and more resistant to adverse environmental conditions and antibiotics (<a href="./references#CD012357-bbs2-0017" title="CammarotaG , SanguinettiM , GalloA , PosteraroB . Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Alimentary pharmacology &amp; therapeutics2012;36(3):222‐30. [PUBMED: 22650647] ">Cammarota 2012</a>). </p> <p>The biofilm complex allows micro‐organisms to adhere to surfaces and proliferate under adverse conditions, and also to cause refractory clinical infections (<a href="./references#CD012357-bbs2-0033" title="Hall‐StoodleyL , StoodleyP . Evolving concepts in biofilm infections. Cellular Microbiology2009;11(7):1034‐43. [PUBMED: 19374653] ">Hall‐Stoodley 2009</a>). Current data show that biofilms are responsible for about 80% of chronic infections. Bacteria in biofilms are 1000 times more resistant to antibiotics and human defences than free‐living ones. Biofilms can worsen resistance rates to antimicrobials by retarding antibiotic diffusion, allowing expression of gene resistance, having chemical properties that impair the effect of some antibiotics, producing beta‐lactamases, decreasing the bacterial growth ratio (target of some antibiotics), and producing reactive oxygen species (<a href="./references#CD012357-bbs2-0017" title="CammarotaG , SanguinettiM , GalloA , PosteraroB . Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Alimentary pharmacology &amp; therapeutics2012;36(3):222‐30. [PUBMED: 22650647] ">Cammarota 2012</a>; <a href="./references#CD012357-bbs2-0029" title="GarciaA , Salas‐JaraMJ , HerreraC , GonzalezC . Biofilm and Helicobacter pylori: from environment to human host. World Journal of Gastroenterology2014;20(19):5632‐8. [PUBMED: 24914322] ">Garcia 2014</a>). </p> <p>N‐acetylcysteine can destabilise the biofilm structure, act synergistically with antibiotics, and has bactericidal effects (<a href="./references#CD012357-bbs2-0011" title="AslamS , TrautnerBW , RamanathanV , DarouicheRO . Combination of tigecycline and N‐acetylcysteine reduces biofilm‐embedded bacteria on vascular catheters. Antimicrobial Agents and Chemotherapy2007;51(4):1556‐8. [PUBMED: 17220399] ">Aslam 2007</a>; <a href="./references#CD012357-bbs2-0012" title="AslamS , DarouicheRO . Role of antibiofilm‐antimicrobial agents in controlling device‐related infections. International Journal of Artificial Organs2011;34(9):752‐8. [PUBMED: 22094553] ">Aslam 2011</a>). Also, NAC has a primary mucolytic effect by reducing the thickness of the gastric mucus layer and has antioxidant properties, both of which may exert beneficial adjuvant effects on <i>H pylori</i> eradication. </p> <p><i>Helicobacter</i> is capable of living as free micro‐organisms in gastric mucus, but more frequently they colonise and form biofilm ecosystems. This was demonstrated in vivo (<a href="./references#CD012357-bbs2-0018" title="CarronMA , TranVR , SugawaC , CoticchiaJM . Identification of Helicobacter pylori biofilms in human gastric mucosa. Journal of Gastrointestinal Surgery2006;10(5):712‐7. [PUBMED: 16713544] ">Carron 2006</a>; <a href="./references#CD012357-bbs2-0021" title="CoticchiaJM , SugawaC , TranVR , GurrolaJ , KowalskiE , CarronMA . Presence and density of Helicobacter pylori biofilms in human gastric mucosa in patients with peptic ulcer disease. Journal of Gastrointestinal Surgery2006;10(6):883‐9. [PUBMED: 16769546] ">Coticchia 2006</a>), and in vitro (<a href="./references#CD012357-bbs2-0054" title="YonezawaH , OsakiT , KurataS , ZamanC , HanawaT , KamiyaS . Assessment of in vitro biofilm formation by Helicobacter pylori . Journal of Gastroenterology and Hepatology2010;25 Suppl 1:S90‐4. [PUBMED: 20586874] ">Yonezawa 2010</a>). </p> <p>A study by Gurbuz and colleagues showed positive results for antibiotics plus NAC, compared with placebo plus antibiotics (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>). An open‐label randomised study of 40 people infected with <i>H pylori</i> showed that pretreatment with NAC plus antibiotics was effective when compared with antibiotics only (<a href="./references#CD012357-bbs2-0016" title="CammarotaG , BrancaG , ArditoF , SanguinettiM , IaniroG , CianciR , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. [PUBMED: 20478402] ">Cammarota 2010</a>). In <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>, another randomised, placebo‐controlled study, it was reported that infection was eradicated in 72.9% of people in the experimental group (NAC plus antibiotic) and in 60.9% in the control group (antibiotics alone). However, there are some studies which reported an additive effect on eradication rates with the use of NAC, although no statistical significance was detected (<a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>; <a href="./references#CD012357-bbs2-0055" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐Line sequential therapy for Helicobacter pylori infection: a randomized controlled pilot trial. Gut and Liver2015;9:1‐6. [PUBMED: 26347514] ">Yoon 2015</a>). In <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>, a double‐blind study, no difference was observed in eradication rates using NAC plus antibiotics. One open‐label study showed similar eradication rates comparing NAC plus quadruple therapy (bismuth, amoxicillin, clarithromycin, and omeprazole) with the same quadruple therapy alone (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>). </p> <p>We hypothesise that treatment failure may occur because of biofilm properties and resistant strains. NAC may have a role in first‐line and rescue therapies because of its properties in biofilm formation. This Cochrane Review intends to examine if NAC, used as an adjuvant to antibiotics, has a benefit in <i>H pylori</i> eradication rates. If so, this could change current practice. </p> </section> <section id="CD012357-sec-0048"> <h3 class="title" id="CD012357-sec-0048">Why it is important to do this review</h3> <p><i>H pylori</i> infection is a major problem for public health, and is one of the most common infectious diseases worldwide. This infection is associated with high morbidity and mortality, poor quality of life, and high costs to healthcare systems. Although several regimens to eradicate <i>H pylori</i> are available, resistance to antibiotics is rising around the world, leading to very low eradication rates (less than 80%) for an infectious disease. </p> <p>Biofilm formation can be a barrier to <i>H pylori</i> eradication (<a href="./references#CD012357-bbs2-0017" title="CammarotaG , SanguinettiM , GalloA , PosteraroB . Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Alimentary pharmacology &amp; therapeutics2012;36(3):222‐30. [PUBMED: 22650647] ">Cammarota 2012</a>). NAC is used as an adjuvant therapy in an attempt to enhance success in eradication rates (<a href="./references#CD012357-bbs2-0026" title="ErmisF , Senocak TasciE . Current Helicobacter pylori treatment in 2014. World Journal of Methodology2015;5(2):101‐7. [PUBMED: 26140276] ">Ermis 2015</a>). </p> <p>The current literature shows some contradictory results for the efficacy of NAC as an adjuvant to antibiotics to eradicate <i>H pylori</i>. While some authors have found positive effects (<a href="./references#CD012357-bbs2-0016" title="CammarotaG , BrancaG , ArditoF , SanguinettiM , IaniroG , CianciR , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. [PUBMED: 20478402] ">Cammarota 2010</a>; <a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>), others have found no effect, or worsening results, when NAC is combined with antibiotics compared with antibiotics only (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>). We conducted this Cochrane Review to explore the uncertainty arising from conflicting results from studies in this area. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012357-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012357-sec-0049">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012357-sec-0158">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012357-sec-0049"></div> <p>To assess the efficacy and safety of N‐acetylcysteine (NAC) as an adjuvant therapy to antibiotics for <i>Helicobacter pylori</i> (<i>H pylori</i>) eradication. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012357-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012357-sec-0050">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012357-sec-0159">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012357-sec-0050"></div> <section id="CD012357-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012357-sec-0052"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs). We included studies reported as full text, those published as abstract only, and unpublished data. We did not include cluster‐randomised, cross‐over, or quasi‐randomised controlled trials. </p> </section> <section id="CD012357-sec-0053"> <h4 class="title">Types of participants</h4> <p>We included adults (equal or over 16 years of age) with a diagnosis of <i>Helicobacter pylori</i> (<i>H pylori</i>) infection, confirmed by urea breath test, stool antigen test, validated immunoglobulin G (IgG), serology, endoscopic biopsies with rapid urease reaction, histology, or culture. We included people in first‐, second‐ or third‐line eradication therapy. </p> </section> <section id="CD012357-sec-0054"> <h4 class="title">Types of interventions</h4> <p>We included studies comparing any antibiotic regimen plus NAC (intervention group) with the same antibiotic regimen without NAC (control group). In the control group, we included studies with a placebo replacing the NAC, as well as studies of antibiotic regimens alone (without placebo). </p> <p>We included studies in which NAC was offered by any route of administration (orally or intravenously) and with any dose of NAC, provided the same route and the same dose were used in both experimental and control groups. </p> <p>We included studies with any drug, dose, or duration of antibiotic regimen, provided they were equal in both groups. </p> <p>We included studies with any drug, dose, or duration of proton pump inhibitor (PPI) when they were part of the eradication therapy tested, provided they were equal in both groups. </p> </section> <section id="CD012357-sec-0055"> <h4 class="title">Types of outcome measures</h4> <section id="CD012357-sec-0056"> <h5 class="title">Primary outcomes</h5> <p>The primary outcomes were:</p> <p> <ul id="CD012357-list-0002"> <li> <p>successful <i>H pylori</i> eradication; and </p> </li> <li> <p>gastrointestinal adverse events (e.g. diarrhoea, nausea, vomiting, or any other reported adverse event). </p> </li> </ul> </p> <p><i>H pylori</i> eradication was defined as a negative test, at least four weeks after treatment, confirmed by urea breath test, stool antigen test, endoscopic biopsies with rapid urease reaction, histology, or culture. We excluded studies that used serology to confirm eradication and/or studies where eradication was confirmed by a test performed within four weeks of treatment, as this could lead to misleading test results (<a href="./references#CD012357-bbs2-0043" title="MalfertheinerP , MegraudF , O'MorainCA , AthertonJ , AxonAT , BazzoliF , et al. Management of Helicobacter pylori infection — the Maastricht IV/ Florence Consensus Report. Gut2012;61(5):646‐64. [PUBMED: 22491499] ">Malfertheiner 2012</a>). </p> <p>In case any study reported outcomes at more than one time point, we considered the last available follow‐up. </p> <p>We planned to contact study authors if a study did not report eradication rates.</p> <p>Reporting of the primary outcomes listed here was not an inclusion criterion for the review. </p> </section> <section id="CD012357-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes were:</p> <p> <ul id="CD012357-list-0003"> <li> <p>allergic adverse events (cutaneous rash, pruritus, or any other reported adverse event); and </p> </li> <li> <p>toxic adverse events (hypotension, headache, anaphylactoid reactions, fever, or any other reported adverse event). </p> </li> </ul> </p> <p>We collected reports of adverse events, regarding the number and type of events (allergic, toxic, etc.), proportions of participants, and interference in compliance. We analysed each type of adverse event separately. </p> <p>Reporting of the secondary outcomes listed here was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD012357-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <p>We placed no restrictions on the date, language or status of publication when searching the electronic databases or other resources. </p> <section id="CD012357-sec-0059"> <h4 class="title">Electronic searches</h4> <p>We conducted a literature search to identify all published and unpublished RCTs. The literature search identified potential studies with no limits to the year of publication. We translated the non‐English language papers and fully assessed them for potential inclusion in the review as necessary. </p> <p>We searched the following electronic databases for identifying potential studies.</p> <p> <ul id="CD012357-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 4) (<a href="./appendices#CD012357-sec-0139">Appendix 2</a>). </p> </li> <li> <p>MEDLINE (1966 to 12 April 2018) (<a href="./appendices#CD012357-sec-0140">Appendix 3</a>). </p> </li> <li> <p>Embase (1988 to 12 April 2018) (<a href="./appendices#CD012357-sec-0141">Appendix 4</a>). </p> </li> <li> <p>CINAHL (1982 to 12 April 2018) (<a href="./appendices#CD012357-sec-0142">Appendix 5</a>). </p> </li> <li> <p>LILACS (1982 to 12 April 2018) (<a href="./appendices#CD012357-sec-0143">Appendix 6</a>). </p> </li> </ul> </p> </section> <section id="CD012357-sec-0060"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references.  We contacted authors of identified studies and asked them to identify other published and unpublished studies. We also contacted manufacturers and experts in the field. </p> <p>We searched for errata or retractions from eligible studies on <a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">PubMed</a> and reported the date this was done within the review. We searched the grey literature databases and clinical trials registers below. </p> <section id="CD012357-sec-0061"> <h5 class="title">Grey literature databases</h5> <p> <ul id="CD012357-list-0005"> <li> <p>Health Management Information Consortium (HMIC) database (<a href="http://www.ovid.com/site/catalog/DataBase/99.jsp" target="_blank">ovid.com/site/catalog/DataBase/99.jsp</a>) </p> </li> <li> <p>National Technical Information Service (NTIS) database (<a href="http://www.ntis.gov/products/ntisdb.aspx" target="_blank">ntis.gov/products/ntisdb.aspx</a>) </p> </li> <li> <p>OpenGrey (<a href="http://www.opengrey.eu" target="_blank">opengrey.eu</a>) </p> </li> </ul> </p> </section> <section id="CD012357-sec-0062"> <h5 class="title">Clinical trials registers/trial result registers</h5> <p> <ul id="CD012357-list-0006"> <li> <p><a href="http://www.astrazenecaclinicaltrials.com/" target="_blank">AstraZeneca Clnical Trials</a> </p> </li> <li> <p><a href="http://www.bms.com/clinical_trials/Pages/clinical_trial_registry.aspx" target="_blank">Bristol‐Myers Squibb Clinical Trial Registry</a> </p> </li> <li> <p><a href="http://www.clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> </p> </li> <li> <p>Current Controlled Trials metaRegister of Controlled Trials (mRCT)</p> <ul id="CD012357-list-0007"> <li> <p>active registers (<a href="http://www.controlled%E2%80%90trials.com/mRCT" target="_blank">controlled‐trials.com/mRCT</a>) </p> </li> <li> <p>archived registers (<a href="http://www.controlled%E2%80%90trials.com/mrct/archived" target="_blank">controlled‐trials.com/mrct/archived</a>) </p> </li> </ul> </li> <li> <p>Eli Lilly and Company Clinical Trial Registry</p> <ul id="CD012357-list-0008"> <li> <p><a href="http://www.lillytrials.com" target="_blank">lillytrials.com</a> </p> </li> <li> <p><a href="http://www.lillytrials.com/initiated/initiated.html" target="_blank">lillytrials.com/initiated</a> </p> </li> </ul> </li> <li> <p><a href="http://www.clinicaltrialsregister.eu/" target="_blank">EU Clinical Trials Register</a> </p> </li> <li> <p><a href="http://www.gsk-clinicalstudyregister.com/" target="_blank">GlaxoSmithKline Clinical Study Register</a> </p> </li> <li> <p><a href="http://www.who.int/trialsearch" target="_blank">International Clinical Trials Registry Platform Search Portal</a> </p> </li> <li> <p><a href="http://clinicaltrials.ifpma.org/no_cache/en/myportal/index.htm" target="_blank">International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Clinical Trials Portal</a> </p> </li> <li> <p><a href="http://www.roche%E2%80%90trials.com/trialResults.action" target="_blank">Roche Clinical Trials Results Database</a> </p> </li> </ul> </p> </section> </section> </section> <section id="CD012357-sec-0063"> <h3 class="title" id="CD012357-sec-0063">Data collection and analysis</h3> <section id="CD012357-sec-0064"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LESF, CSB) independently screened titles and abstracts of all the potential studies we identified as a result of the search, and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full‐text study reports/publications, and two review authors (LESF, CSB) independently screened the full text and identified studies for inclusion and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third review author (RR). We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD012357-bbs2-0047" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>), and 'Characteristics of excluded studies' table. </p> </section> <section id="CD012357-sec-0065"> <h4 class="title">Data extraction and management</h4> <p>We used a Cochrane standard data collection form (<a href="./references#CD012357-bbs2-0025" title="Cochrane Editorial Resources Committee (ERC). ERC data collection form for intervention review for RCTs only. www.community‐archive.cochrane.org/sites/default/files/uploads/forums/u389/ERC%20data%20collection%20form%20for%20intervention%20reviews%20for%20RCTs%20only.doc (accessed 12 September 2016). ">ERC 2014</a>) for study characteristics and outcome data, which had been piloted on at least one study in the review. Two review authors (LESF, CGZ) extracted the following study characteristics from the included studies. </p> <p> <ul id="CD012357-list-0009"> <li> <p>General information of the study: report title, year of publication, author contacts, and publication type (abstract or full report). </p> </li> <li> <p>Methods: aim of study, study design, unit of allocation, start date, end date, duration of participation, and ethical approval. </p> </li> <li> <p>Participants: population description, setting, inclusion criteria, exclusion criteria, age, method of recruitment, informed consent obtained, total number randomised, baseline imbalances, withdrawals and exclusions, gender, race/ethnicity, severity of condition, comorbidities, diagnostic criteria, subgroups measured, subgroups reported, and other relevant sociodemographics. </p> </li> <li> <p>Interventions: number randomised in each group, dose, duration of treatment period, timing, delivery, providers, cointerventions, economic information, resource requirements, integrity of delivery, and compliance. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, time points measured and reported, outcome definition, person measuring/reporting, unit of measurement, scales, imputation of missing data, assumed risk estimates, and power. </p> </li> <li> <p>Notes: funding for study, and notable conflicts of interest of study authors.</p> </li> </ul> </p> <p>Two review authors (LESF, CGZ) independently extracted outcome data from included studies. We noted in the 'Characteristics of included studies' table if outcome data were reported in an unusable way. We resolved disagreements by consensus or by involving a third review author (RR). One review author (LESF) copied across the data from the data collection form into the Review Manager 5 file (<a href="./references#CD012357-bbs2-0049" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We double‐checked that the data were entered correctly by comparing the study reports with how the data were presented in the review. A second review author spot‐checked study characteristics for accuracy against the study report. </p> </section> <section id="CD012357-sec-0066"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LESF, ALCM) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012357-bbs2-0035" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Any disagreement was resolved by discussion or by involving a third review author (RR). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD012357-list-0010"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ul> </p> <p>For each study, we graded each potential source of bias as high, low, or unclear, and provided a quote form the study report together with a justification for our judgment in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary. Where information on risk of bias related to unpublished data or correspondence with a researcher, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD012357-sec-0067"> <h5 class="title">Assessment of bias in conducting the review</h5> <p>We conducted the review according to this published protocol and reported any deviations from it in <a href="#CD012357-sec-0149">Differences between protocol and review</a>. </p> </section> </section> <section id="CD012357-sec-0068"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios and continuous data as a mean differences or standardised mean differences, providing 95% confidence intervals for the results. We ensured that higher scores for continuous outcomes had the same meaning for the particular outcome, explained the direction of effect to the reader, and reported where the directions were reversed (if this was necessary). </p> <p>We undertook meta‐analyses only where this was meaningful, i.e. if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. </p> <p>A common way that researchers indicate when they have skewed data is by reporting medians and interquartile ranges. When we encountered this, we noted that the data were skewed and considered the implication of this. </p> <p>Where multiple study arms were reported in a single study, we included only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were entered into the same meta‐analysis, we halved the control group to avoid double‐counting. </p> </section> <section id="CD012357-sec-0069"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual, and a single measurement of each outcome for each participant was collected and analysed. </p> </section> <section id="CD012357-sec-0070"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). If we could not obtain the numerical outcome data, we planned to carry out an intention‐to‐treat analysis, assuming that missing participants have failed the treatment. </p> </section> <section id="CD012357-sec-0071"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the studies in each analysis (<a href="./references#CD012357-bbs2-0034" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). If we identified substantial heterogeneity, we explored it by prespecified subgroup analysis. We investigated statistical diversity by estimates of treatment effect through forest plots produced using Review Manager 5 software (<a href="./references#CD012357-bbs2-0049" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We considered an I<sup>2</sup> value greater than 50% as substantial heterogeneity (<a href="./references#CD012357-bbs2-0035" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). In this case, as well as in the presence of clinical or methodological heterogeneity (or both), we used a random‐effects model, rather than a fixed‐effect model. </p> </section> <section id="CD012357-sec-0072"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to contact study authors, in order to ask them to provide missing outcome data. Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis<b>. </b> </p> <p>We could not pool more than 10 studies, so we did not create a funnel plot to explore possible publication biases. </p> </section> <section id="CD012357-sec-0073"> <h4 class="title">Data synthesis</h4> <p>We combined the results across studies, and used a random‐effects model meta‐analysis for dichotomous and continuous outcomes if participants, interventions, comparisons, and outcomes were sufficiently similar to make clinical sense. </p> </section> <section id="CD012357-sec-0074"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out the following subgroup analyses.</p> <p> <ul id="CD012357-list-0011"> <li> <p>Line of treatment (participants in first‐ versus second‐ versus third‐line therapy): we expected that those receiving the interventions of interest as a first‐line therapy have better outcomes. </p> </li> </ul> <ul id="CD012357-list-0012"> <li> <p>Smoking status (smokers versus non‐smokers: we expected that smoking participants have poorer eradication rates (<a href="./references#CD012357-bbs2-0038" title="ItskovizD , BoltinD , LeibovitzhH , Tsadok PeretsT , ComaneshterD , CohenA , et al. Smoking increases the likelihood of Helicobacter pylori treatment failure. Digestive and Liver Disease2017;49(7):764‐8. [PUBMED: 28427781] ">Itskoviz 2017</a>). </p> </li> </ul> <ul id="CD012357-list-0013"> <li> <p>Type of test used to assess eradication (urea breath test versus stool antigen test versus endoscopic methods): these tests are different in terms of accuracy. </p> </li> </ul> </p> <p>We used the outcome of successful eradication rate in subgroup analysis. We used the I² statistic to measure heterogeneity among the subgroups in each analysis. If we identified substantial heterogeneity (more than 50%), we explored it using the subgroup analyses prespecified above. Additionally, in case of substantial heterogeneity (clinical , statistical or methodological), we used a random‐effects model rather than a fixed‐effect model. </p> </section> <section id="CD012357-sec-0075"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis, defined a priori, to assess the robustness of our conclusions. This involved excluding studies with a high risk of bias (those classified as having high risk of bias in at least one of the following criteria: randomisation, allocation concealment, and blinding). We also performed a post‐hoc sensitivity analysis, in which we excluded studies that tested antibiotic regimens no longer recommended in current clinical practice due to low efficacy. </p> <section id="CD012357-sec-0076"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided making recommendations for practice if the results of the review were not statistically significant, and our implications for research gave the reader a clear sense of where the focus of any future research in the area should be, and what the remaining uncertainties are. </p> </section> <section id="CD012357-sec-0077"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table for the comparison: any antibiotic regimen plus NAC versus the same antibiotic regimen alone. </p> <p>Into this comparison, we have created subgroups with each correspondent analysis for:</p> <p> <ul id="CD012357-list-0014"> <li> <p>triple therapies plus NAC versus triple therapies alone;</p> </li> <li> <p>dual therapies plus NAC versus dual therapies alone;</p> </li> <li> <p>sequential therapy plus NAC versus sequential therapy alone;</p> </li> <li> <p>bismuth quadruple therapy plus NAC versus bismuth quadruple therapy alone;</p> </li> <li> <p>antibiotic monotherapy plus NAC, without PPI, versus antibiotic monotherapy alone, without PPI. </p> </li> </ul> </p> <p>We had planned to create a 'Summary of Findings' table for the comparisons below, but we did not find studies for them. </p> <p> <ul id="CD012357-list-0015"> <li> <p>Concomitant therapy plus NAC versus concomitant therapy alone.</p> </li> <li> <p>Hybrid therapy plus NAC versus hybrid therapy alone.</p> </li> <li> <p>Quinolone‐based therapy plus NAC versus quinolone‐based therapy alone (We found a study that used a quinolone plus bismuth instead of amoxicillin. We have considered this combination as a triple therapy.) </p> </li> </ul> </p> <p>Definitions for these regimens are as follows.</p> <p> <ul id="CD012357-list-0016"> <li> <p>Triple therapies = PPI + two antibiotics.</p> </li> <li> <p>Dual therapies = PPI + one antibiotic.</p> </li> <li> <p>Sequential therapy = PPI + amoxicillin (five days), followed by PPI + clarithromycin + metronidazole (five days). </p> </li> <li> <p>Bismuth quadruple therapy = PPI + bismuth + tetracycline + metronidazole (10 to 14 days). </p> </li> <li> <p>Concomitant therapy = PPI + clarithromycin + metronidazole + amoxicillin (7 to 10 days). </p> </li> <li> <p>Hybrid therapy = PPI + amoxicillin (10 days), followed by PPI + clarithromycin + metronidazole + amoxicillin (10 days). </p> </li> <li> <p>Quinolone‐based therapy = PPI + quinolone + amoxicillin (10 days).</p> </li> </ul> </p> <p>We assessed the body of the evidence for all pre‐defined outcomes: successful <i>H pylori</i> eradication, adverse events (gastrointestinal, cutaneous, toxic, and other serious adverse events)<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD012357-bbs2-0032" title="GuyattG , GuttermanD , BaumannMH , Addrizzo‐HarrisD , HylekEM , PhillipsB , et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest2006;129(1):174‐81. [PUBMED: 16424429] ">Guyatt 2006</a>). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012357-bbs2-0036" title="HigginsJPT , AltmanDG , SterneJAC , Cochrane Statistical Methods Group, Cochrane Bias Methods Group. Chapter 8.5: The Cochrane Collaboration's tool for assessing risk of bias. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>; <a href="./references#CD012357-bbs2-0050" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>), and used GRADEpro GDT to generate the tables (<a href="./references#CD012357-bbs2-0030" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 9 April 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>). We used footnotes to record and justify all decisions to downgrade or upgrade our assessments of the quality of evidence, and made comments to aid the reader's understanding of the review where necessary. We considered whether there was any additional outcome information that was not able to be incorporated into meta‐analyses, noted this in the comments, and stated if it supported or contradicted the information from the meta‐analyses. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012357-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012357-sec-0078"></div> <section id="CD012357-sec-0079"> <h3 class="title">Description of studies</h3> <section id="CD012357-sec-0080"> <h4 class="title">Results of the search</h4> <p>Initially, 765 records were retrieved through database searching. After resolving duplicates, we selected 226 records for the screening process. After discarding 208 reports that were clearly not relevant, we identified 18 records as potentially eligible studies. After the full‐text assessment, we included eight studies from 18 references in the review. The process of selection of the studies is described in <a href="#CD012357-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012357-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012357-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012357-sec-0081"> <h4 class="title">Included studies</h4> <p>Full details on the individual eight studies are available in <a href="./references#CD012357-sec-0151" title="">Characteristics of included studies</a>. We contacted the authors of all studies in order to obtain missing information on methods used in their studies, but we received no feedback from them. </p> <section id="CD012357-sec-0082"> <h5 class="title">Design</h5> <p>All studies were randomised controlled trials (RCTs), with a parallel design with two groups of comparison. </p> </section> <section id="CD012357-sec-0083"> <h5 class="title">Sample Size</h5> <p>There were 559 participants enrolled in this review and the sample size of studies ranged from 34 (<a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>), to 121 (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>). </p> </section> <section id="CD012357-sec-0084"> <h5 class="title">Setting</h5> <p>All studies recruited outpatients who were referred to endoscopy centres with different indications for endoscopy examination. Studies were performed in several different countries: Italy (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>), Switzerland (<a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>), Iran (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>), Denmark (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>),Turkey (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>), and South Korea (<a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). The first of the included studies published was the Zala and colleagues in 1994 (<a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>), and the most recent was published in 2015 (<a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>). </p> </section> <section id="CD012357-sec-0085"> <h5 class="title">Participants</h5> <p>All participants were adults between 17 and 76 years with a gender distribution of 287 males and 285 females. The method of diagnosis of <i>Helicobacter pylori</i> (<i>H pylori</i>) infection varied between histology, rapid urease test, stool antigen test, urea breath test or culture, according to each study protocol. </p> <p>The conditions affecting participants with <i>H pylori</i> infection were dyspepsia, peptic ulcer disease, gastric cancer or dysplasia, family history of gastric cancer, gastritis, oesophagitis, and duodenitis. </p> <p>Only one study reported the ethnicity of participants (<a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>), although the studies were performed in a wide range of countries as described above. </p> </section> <section id="CD012357-sec-0086"> <h5 class="title">Interventions and comparisons</h5> <p>The studies tested several different antibiotic regimens, using the same antibiotic drugs (dose, frequency, duration) for both comparison arms. The intervention groups received N‐acetylcysteine (NAC) and the controls did not. NAC dose ranged from 600 mg/day to 1800 mg/day. The duration of treatment with antibiotics ranged from 7 to 28 days according to each study protocol. Three studies tested one antibiotic plus NAC (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>), three studies tested two antibiotics plus NAC (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>), and two studies tested three antibiotics plus NAC (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). All studies included a proton pump inhibitor (PPI) in both treatment arms, except the study by Hansen and colleagues (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>). Compliance was reported in four studies (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). All drugs were delivered in capsules or pills and administered orally. NAC was tested in first‐line therapy in two studies (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>), and in rescue therapy in one study (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>). The other studies included did not mention clearly if they were testing first‐ or second‐line eradication therapy. The comparisons tested are described in <a href="#CD012357-tbl-0002">Table 1</a>. </p> <div class="table" id="CD012357-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control (no NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally twice daily plus amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily and clarithromycin 500 mg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, placebo controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally twice daily plus amoxicillin 500 mg four times daily, bismuth citrate 120 mg four times daily, omeprazole 20 mg twice daily, and clarithromycin 500 mg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 400 mg orally twice daily plus sequential therapy with rabeprazole 20 mg and amoxicillin 1g (both twice daily) for the first five days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg (all drugs twice daily) for the remaining five days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally twice daily plus ciprofloxacin 500 mg twice daily, pantoprazole 40 mg twice daily and bismuth subcitrate 120 mg two tablets twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, placebo controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally once a day for one week before a culture‐guided regimen, including a proton pump inhibitor (PPI) plus two antibiotics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 400 mg orally three times a day plus clarithromycin 500 mg twice daily and lansoprazole 30 mg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally twice daily plus omeprazole 40 mg twice daily and amoxicillin 750 mg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally three times a day plus amoxicillin 375 mg three times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, placebo controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NAC: N‐acetylcysteine</p> </div> </div> </section> <section id="CD012357-sec-0087"> <h5 class="title">Outcomes</h5> <p>The following outcomes of interest were assessed by the included studies.</p> <p> <ul id="CD012357-list-0017"> <li> <p>Eradication rate: all included studies.</p> </li> <li> <p>Adverse events: five studies (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). </p> </li> </ul> </p> <p>Eradication rates were tested and described in all included studies. Criteria for considering eradication were different among studies.Three studies defined eradication as a negative result in urea breath test alone (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>). One study considered eradication as a negative result in either urea breath test, histology, or rapid urease test (<a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). One study considered eradication as a negative result in stool antigen test (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>), while another defined eradication as a negative result in rapid urease test and histology (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>). Finally, two studies considered eradication as a negative result in all of the following: histology, rapid urease test, and culture (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). </p> <p>The study by Hansen and colleagues used six months after treatment as the time point for eradication assessment (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>), in contrast with all others which used four weeks after the end of treatment<i>.</i> </p> <p>The most observed class of adverse event were gastrointestinal symptoms. The adverse events cited in the studies were: abdominal pain or discomfort, stomatitis, diarrhoea, vomiting, nausea, dyspepsia, epigastric soreness, regurgitation, abdominal distention, metallic or altered taste. Other adverse events observed included skin rash, headache, dizziness, and thirst. </p> </section> </section> <section id="CD012357-sec-0088"> <h4 class="title">Excluded studies</h4> <p>We did not exclude any studies following full‐text assessment.</p> <section id="CD012357-sec-0089"> <h5 class="title">Ongoing studies</h5> <p>There are two ongoing studies. One study intends to assess second‐line eradication rate of <i>H pylori</i> by adding NAC or metronidazole to the conventional triple therapy (<a href="./references#CD012357-bbs2-0009" title="NCT01572597 . Increased re‐eradication rate of Helicobacter pylori by adding N‐acetylcysteine or metronidazole to the triple therapy [Increased second‐line eradication rate of Helicobacter pylori by adding N‐acetylcysteine or metronidazole to the conventional triple therapy]. clinicaltrials.gov/ct2/show/NCT01572597 (first received 6 April 2012). ">NCT01572597</a>). The other is testing the efficacy of acetylcysteine‐containing triple therapy in the first‐line treatment of <i>H pylori</i> infection (<a href="./references#CD012357-bbs2-0010" title="NCT02249546 . Efficacy of acetylcysteine‐containing triple therapy in the first line of Helicobacter pylori infection [Comparison of the efficacy of triple therapy with or without acetylcysteine in the first line of Helicobacter pylori infection ‐ a multicenter randomized comparative trial]. clinicaltrials.gov/ct2/show/NCT02249546 (first received 25 September 2014). ">NCT02249546</a>). These studies are listed in <a href="./references#CD012357-sec-0152" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD012357-sec-0090"> <h3 class="title">Risk of bias in included studies</h3> <p>The 'Risk of bias' assessments for all included studies are depicted in <a href="#CD012357-fig-0002">Figure 2</a> and <a href="#CD012357-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012357-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012357-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012357-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD012357-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012357-sec-0091"> <h4 class="title">Allocation</h4> <p>Random sequence allocation method was adequate in three studies (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>), which we classified as having a low risk of bias for this domain. The remaining studies did not present the method used and we judged them as having an unclear risk of bias. </p> <p>None of the studies provided information about allocation concealment methods (even after email contact), and we classified them as having an unclear risk of bias. </p> </section> <section id="CD012357-sec-0092"> <h4 class="title">Blinding</h4> <p>We assessed performance and detection bias for each outcome of interest.</p> <section id="CD012357-sec-0093"> <h5 class="title">Blinding of participants and personnel</h5> <section id="CD012357-sec-0094"> <h6 class="title">Eradication rate</h6> <p>Although the method of assessment of eradication varied, this outcome was always assessed through an objective laboratory test. Therefore, we judged that performance bias was unlikely to influence results and we classified all studies as having a low risk of bias. </p> </section> <section id="CD012357-sec-0095"> <h6 class="title">Gastrointestinal, allergic and toxic adverse events</h6> <p>Three studies did not assess these outcomes (<a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>). Another study did not provide sufficient information (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>), so we classified it as having an unclear risk of bias. We considered all other studies to have a high risk of bias provided they were performed in an open‐label design. </p> </section> </section> <section id="CD012357-sec-0096"> <h5 class="title">Blinding of outcome assessment</h5> <section id="CD012357-sec-0097"> <h6 class="title">Eradication rate</h6> <p>The method of assessment of eradication was always a laboratory objective test, meaning detection bias was very unlikely. We judged all studies as having a low risk of bias. </p> </section> <section id="CD012357-sec-0098"> <h6 class="title">Gastrointestinal, allergic and toxic adverse events</h6> <p>Three studies did not assess these outcomes (<a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>). Four studies were open‐label, with no blinding for the outcome assessor, and so we considered them to be at high risk of bias (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). The final study did not provide sufficient information and so we judged it as having an unclear risk of bias (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>). </p> </section> </section> </section> <section id="CD012357-sec-0099"> <h4 class="title">Incomplete outcome data</h4> <p>We judged one study to have an unclear risk of bias because there was a loss of 5% of participants with an unbalance between groups and no reason provided (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>). </p> <p>We deemed three studies to have a high risk of bias. In <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>, there was a loss of 32.7% of the participants and no reason was provided for this. In <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>, there was a loss of 24.7% of the participants. Reasons were provided, but no information about the balance between groups or the methods used for data imputation were given. Finally, in <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>, there was a loss of 18% of the participants (with a balance between groups). An intention‐to‐treat (ITT) analysis was used, but the methods used for data imputation were also not provided. </p> <p>We classified four studies as having a low risk of bias for this domain. There were no losses in three studies (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). In <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>, there was a loss of 6% of the participants in the control group, which we judged as being unlikely to influence the results. </p> </section> <section id="CD012357-sec-0100"> <h4 class="title">Selective reporting</h4> <p>We judged all studies to be free from selective outcome reporting provided they described all outcomes planned. </p> </section> <section id="CD012357-sec-0101"> <h4 class="title">Other potential sources of bias</h4> <p>We judged two studies as having an unclear risk of potential sources of bias. One study declared that Astra Group provided NAC and placebo but provided no information about Astra Group's influence in design, analysis or reporting (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>). In the other study, the author did not report funding sources or conflict of interest (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>). There was insufficient information to allow judgement about this. </p> </section> </section> <section id="CD012357-sec-0102"> <h3 class="title" id="CD012357-sec-0102">Effects of interventions</h3> <p>See: <a href="./full#CD012357-tbl-0001"><b>Summary of findings for the main comparison</b> Any antibiotic regimen plus N‐acetylcysteine compared to the same regimen without N‐acetylcysteine (with or without placebo) for <i>Helicobacter pylori</i> infection</a> </p> <section id="CD012357-sec-0103"> <h4 class="title">Any antibiotic regimen plus N‐acetylcysteine (NAC) versus the same antibiotic regimen without NAC </h4> <section id="CD012357-sec-0104"> <h5 class="title">Eradication rate</h5> <p>All eight included studies provided data for this outcome (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). In <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>, eradication rates were assessed immediately after treatment (this was termed "clearance"), and at six months after treatment (this was termed "eradication"). For this study, we considered eradication data available at six months, following our criteria for studies that have assessed outcomes at more than one time point, as mentioned in this review's protocol (<a href="./references#CD012357-bbs2-0028" title="FontesLES , BatistaCS , MartimbiancoALC , ZaninCG , RieraR . N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD012357] ">Fontes 2016</a>). All studies apart from one included a proton pump inhibitor (PPI) in both treatment arms. </p> <p>Overall, we are uncertain whether the addition of NAC to antibiotics improves <i>H pylori</i> eradication rates compared with the addition of placebo or no NAC (38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low certainty of evidence) (<a href="./references#CD012357-fig-0004" title="">Analysis 1.1</a>). </p> <section id="CD012357-sec-0105"> <h6 class="title">Subgroup analysis: triple therapies (PPI + two antibiotics) plus NAC versus triple therapies without NAC </h6> <p>Three studies provided data for this outcome (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>). We are uncertain whether the addition of NAC to triple therapy improves eradication rates compared with the addition of placebo or no NAC (51.6% versus 69.3%, RR 0.62, 95% CI 0.42 to 0.91; participants = 177; studies = three) (<a href="./references#CD012357-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012357-sec-0106"> <h6 class="title">Subgroup analysis: dual therapies (PPI + one antibiotic) plus NAC versus dual therapies without NAC </h6> <p>Two studies provided data for this outcome (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). We are uncertain whether NAC improves eradication rates compared with the addition of placebo or no NAC (29.8% versus 57.8%, RR 0.62, 95% CI 0.42 to 0.90; participants = 92; studies = two) (<a href="./references#CD012357-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012357-sec-0107"> <h6 class="title">Subgroup analysis: sequential therapy (PPI + amoxicillin (five days), followed by PPI + clarithromycin + metronidazole (five days)) plus NAC versus sequential therapy without NAC </h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). We are uncertain whether NAC improves eradication rates compared with the addition of placebo or no NAC (58% versus 67.3%, RR 0.78, 95% CI 0.46 to 1.30; participants = 99; studies = one) (<a href="./references#CD012357-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012357-sec-0108"> <h6 class="title">Subgroup analysis: bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) plus NAC versus bismuth quadruple therapy without NAC </h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>). We are uncertain whether NAC improves eradication rates compared with the addition of placebo or no NAC (81.7% versus 82%, RR 0.98, 95% CI 0.46 to 2.09; participants = 121; studies = one) (<a href="./references#CD012357-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012357-sec-0109"> <h6 class="title">Subgroup analysis: no PPI, antibiotic monotherapy plus NAC versus antibiotic monotherapy without NAC </h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>). We are uncertain whether NAC improves eradication rates compared with the addition of placebo or no NAC (54.2% versus 60%, RR 1.14, 95% CI 0.66 to 1.97; participants = 70; studies = one) (<a href="./references#CD012357-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012357-sec-0110"> <h6 class="title">Subgroup analysis: smoking status</h6> <p>The results were based on only one study (<a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>). We are uncertain whether NAC improves eradication rates in smokers (50% versus 57.1%, RR 0.86, 95% CI 0.27 to 2.77; participants = 13; studies = one) or in non‐smokers (62.8% versus 74.1%, RR 0.69, 95% CI 0.33 to 1.45; participants = 66; studies = 1) (<a href="./references#CD012357-fig-0008" title="">Analysis 1.5</a>). </p> <p>The test for subgroup differences showed no interaction related to smoking status (Chi² = 0.09, df = 1 (P = 0.77), I² = 0%). </p> </section> <section id="CD012357-sec-0111"> <h6 class="title">Subgroup analysis: line of treatment</h6> <p>We did not find sufficient information in included studies to organise subgroups as first‐, second‐, third‐line as we planned. Only one study stated that they were testing NAC in first‐line therapy (<a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>), and one study stated that they tested NAC in association with culture‐guided antibiotic therapy, after at least four failures (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>). </p> </section> <section id="CD012357-sec-0112"> <h6 class="title">Subgroup analysis: type of test used to assess eradication</h6> <p>Four studies tested eradication using the urea breath test (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). NAC may improve eradication rates measured this way, compared with the addition of placebo or no NAC (31.3% versus 46%, RR 0.67, 95% CI 0.49 to 0.91; participants = 276; studies = four) (<a href="./references#CD012357-fig-0009" title="">Analysis 1.6</a>). </p> <p>Three studies used endoscopic methods (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). We are uncertain whether NAC improves eradication rates measured this way, compared with the addition of placebo or no NAC (43.7% versus 57.3%, RR 0.75, 95% CI 0.48 to 1.17; participants = 162; published studies = three) (<a href="./references#CD012357-fig-0009" title="">Analysis 1.6</a>). </p> <p>Finally, one study used a stool antigen test (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>). We are uncertain whether NAC improves eradication rates measured this way, compared with the addition of placebo or no NAC (18% versus 18.3%, RR 0.98, 95% CI 0.46 to 2.49; participants = 121 ; published studies = one) (<a href="./references#CD012357-fig-0009" title="">Analysis 1.6</a>) </p> <p><b>Sensitivity analysis: currently used regimens</b> </p> <p>Five studies tested eradication with currently used antibiotic regimens (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>; <a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). Adding NAC to these regimens may improve eradication rates, compared with adding placebo or no NAC (27.2 % versus 37.6 %, RR 0.71, 95% CI 0.53 to 0.94; participants = 397 ; published studies = five) (<a href="./references#CD012357-fig-0010" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD012357-sec-0113"> <h5 class="title">Gastrointestinal adverse events</h5> <p>Five included studies provided data for this outcome (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). </p> <p>We are uncertain whether NAC leads to a higher rate of gastrointestinal adverse events compared with the addition of placebo or no NAC (23.9% versus 18.9%, RR 1.25, 95% CI 0.85 to 1.85; participants = 336; studies = five; very low certainty of evidence) (<a href="./references#CD012357-fig-0005" title="">Analysis 1.2</a>). </p> <section id="CD012357-sec-0114"> <h6 class="title">Triple therapies plus NAC versus triple therapies without NAC</h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>). We are uncertain whether NAC leads to a higher rate of gastrointestinal adverse events compared with the addition of placebo or no NAC (40% versus 30%, RR 1.33 , 95% CI 0.57 to 3.14; participants = 40; studies = one) (<a href="./references#CD012357-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012357-sec-0115"> <h6 class="title">Dual therapies plus NAC versus dual therapies without NAC</h6> <p>Two studies provided data for this outcome (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). No events were observed in both arms of the included studies (RR not estimable; participants = 92; studies = two) (<a href="./references#CD012357-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012357-sec-0116"> <h6 class="title">Sequential therapy plus NAC versus sequential therapy without NAC</h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). We are uncertain whether NAC leads to a higher rate of gastrointestinal adverse events compared with the addition of placebo or no NAC (26.8% versus 26.1%, RR 1.02, 95% CI 0.50 to 2.10; participants = 83; studies = one) (<a href="./references#CD012357-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012357-sec-0117"> <h6 class="title">Bismuth quadruple therapy plus NAC versus bismuth quadruple therapy without NAC</h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>). We are uncertain whether NAC leads to a higher rate of gastrointestinal adverse events compared with the addition of placebo or no NAC (34.4% versus 25%, RR 1.38, 95% CI 0.79 to 2.41; participants = 121; studies = one) (<a href="./references#CD012357-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012357-sec-0118"> <h6 class="title">No PPI, antibiotic monotherapy plus NAC versus antibiotic monotherapy without NAC</h6> <p>None of the studies assessed this outcome.</p> </section> </section> <section id="CD012357-sec-0119"> <h5 class="title">Allergic adverse events</h5> <p>Five included studies provided data for this outcome (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). </p> <p>We are uncertain whether NAC leads to a higher rate of allergic adverse events compared with the addition of placebo or no NAC (1.2% versus 0%, RR 2.98, 95% CI 0.32 to 27.74; participants = 336 ; published studies = five; very low certainty of evidence) (<a href="./references#CD012357-fig-0006" title="">Analysis 1.3</a>). </p> <section id="CD012357-sec-0120"> <h6 class="title">Triple therapies plus NAC versus triple therapies without NAC</h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>). No events were observed in both arms (RR not estimable; participants = 40; studies = one) (<a href="./references#CD012357-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD012357-sec-0121"> <h6 class="title">Dual therapies plus NAC versus dual therapies without NAC</h6> <p>Two studies provided data for this outcome (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). We are uncertain whether NAC leads to a higher rate of allergic adverse events compared with the addition of placebo or no NAC (2.2% versus 0%, RR 3.00, 95% CI 0.13 to 68.84; participants = 92; studies = two) (<a href="./references#CD012357-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD012357-sec-0122"> <h6 class="title">Sequential therapy plus NAC versus sequential therapy without NAC</h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). No events were observed in both arms (RR not estimable; participants = 83; studies = one) (<a href="./references#CD012357-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD012357-sec-0123"> <h6 class="title">Bismuth quadruple therapy plus NAC versus bismuth quadruple therapy without NAC</h6> <p>One study provided data for this outcome (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>). We are uncertain whether NAC leads to a higher rate of allergic adverse events compared with the addition of placebo or no NAC (1.2% versus 0%, RR 2.95, 95% CI 0.12 to 71.05; participants = 121; studies = one) (<a href="./references#CD012357-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD012357-sec-0124"> <h6 class="title">No PPI, antibiotic monotherapy plus NAC versus antibiotic monotherapy without NAC</h6> <p>None of the studies assessed this outcome.</p> </section> </section> <section id="CD012357-sec-0125"> <h5 class="title">Toxic adverse events</h5> <p>There were no reports of toxic adverse events amongst the five studies that reported this outcome (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>; <a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>; <a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012357-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012357-sec-0126">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012357-sec-0187">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012357-sec-0126"></div> <section id="CD012357-sec-0127"> <h3 class="title" id="CD012357-sec-0127">Summary of main results</h3> <p>This systematic review assessed the efficacy and safety of N‐acetylcysteine (NAC) as an adjuvant therapy to antibiotics for <i>Helicobacter pylori</i> (<i>H pylori</i>) eradication. We found eight randomised controlled trials (RCTs), recruiting 559 participants. The results are depicted in <a href="./full#CD012357-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>The studies were different with respect to the participants (i.e. whether they had been previously treated or not), type of antibiotics, dose of NAC, duration of treatment, and measurement of the outcomes. </p> <p> <ul id="CD012357-list-0018"> <li> <p>Eradication rates: we are uncertain whether the addition of NAC to antibiotics improves <i>H pylori</i> eradication rates compared with the addition of placebo or no NAC. Due to the clinical, statistical and methodological heterogeneity found in included studies, and the uncertainty observed when we analysed therapy subgroups, any possible beneficial effect of NAC should be regarded cautiously. Furthermore, we are uncertain if there are differences in eradication rates between smokers and non‐smokers who use NAC in addition to antibiotics. </p> </li> <li> <p>Adverse events: we are uncertain whether the addition of NAC to antibiotics is associated with a higher risk of gastrointestinal or allergic adverse events, compared with the addition of placebo or no NAC. There were no reports of toxic adverse events amongst the included studies. </p> </li> </ul> </p> </section> <section id="CD012357-sec-0128"> <h3 class="title" id="CD012357-sec-0128">Overall completeness and applicability of evidence</h3> <p>The regimens compared in the included studies were very different. Overall, the studies had small sample sizes and measured the outcomes in the short term, using different tests. Importantly, three studies tested regimens that are no longer recommended due to low efficacy (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>; <a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>; <a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>), and their external validity must be regarded cautiously. We performed a post‐hoc sensitivity analysis to see whether the results are still applicable when these studies are excluded. In contrast with the main analysis, the results were in favour of adding NAC to antibiotics. </p> <p>The following treatment schemes, with versus without NAC, were assessed.</p> <p> <ol id="CD012357-list-0019"> <li> <p>NAC plus amoxicillin, a proton pump inhibitor (PPI), and clarithromycin (<a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a>). </p> </li> <li> <p>NAC plus amoxicillin, a PPI, bismuth citrate, and clarithromycin (<a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a>). </p> </li> <li> <p>NAC plus sequential therapy with amoxicillin and a PPI for the first five days, followed by a PPI, clarithromycin, and metronidazole for the remaining five days (<a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a>). </p> </li> <li> <p>NAC plus ciprofloxacin, a PPI, and bismuth subcitrate (<a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a>). </p> </li> <li> <p>NAC for one week before a culture‐guided regimen including a PPI plus two antibiotics (<a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a>). </p> </li> <li> <p>NAC plus clarithromycin, and a PPI (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>). </p> </li> <li> <p>NAC plus amoxicillin and a PPI (<a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a>). </p> </li> <li> <p>NAC plus amoxicillin (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>). </p> </li> </ol> </p> <p>Therefore, the available evidence is limited to these specific interventions, and a restricted follow‐up period of four weeks. We did not find two or more studies testing the same drug regimen. </p> <p>Doses of NAC ranged from 600 mg to 1800 mg among studies, which led to uncertainty concerning optimal dose and safety issues. </p> <p>There is a lack of evidence for the following outcomes:</p> <p> <ul id="CD012357-list-0020"> <li> <p>eradication rates of currently recommended regimens, such as concomitant therapy, hybrid therapy, and conventional bismuth triple therapy (there were no studies for these comparisons of interest); </p> </li> <li> <p>adverse events: the outcomes were not originally planned at the protocol stage of the included RCTs, or they were not properly reported. </p> </li> </ul> </p> <p>We considered the studies identified insufficient to address all of the objectives of the review. </p> </section> <section id="CD012357-sec-0129"> <h3 class="title" id="CD012357-sec-0129">Quality of the evidence</h3> <p>We have presented our assessments of the certainty of the body of evidence obtained for each outcome and comparison in <a href="./full#CD012357-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>For eradication rate, we judged the certainty of the pooled evidence as very low (eight studies, 559 participants). We downgraded our assessment of the certainty of the evidence because of serious or very serious concerns related to the 'Risk of bias' assessment, inconsistency and imprecision amongst included studies. </p> <p>For adverse events, we judge the certainty of the pooled evidence as low to very low (five studies, 336 participants). We downgraded our assessment of the certainty of the evidence because of serious or very serious concerns related to the 'Risk of bias' assessment and imprecision amongst included studies. </p> <p>The overall certainty of the evidence was reduced at study or outcome levels due to the poor methodological quality (mainly related to generation of allocation sequence, allocation concealment, and blinding of participants, personnel or outcome assessors, the last domain for adverse event outcomes), or due to imprecision and inconsistency (mainly related to wide confidence intervals and small samples). The small sample size that each study contributed to each comparison can be associated with an increased risk of type 2 error. </p> </section> <section id="CD012357-sec-0130"> <h3 class="title" id="CD012357-sec-0130">Potential biases in the review process</h3> <p>To avoid the introduction of bias in this review, we followed all of the recommendations on searching, study selection, data collection, and analysis in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011203.pub2/full#CD011203-bbs2-0022" target="_blank">Higgins 2011</a>). </p> <p>The strengths of this review include an extensive literature search and the use of intention‐to‐treat analyses for dichotomous data. The eradication rate was measured in all included studies by an objective test, reducing the risk of bias related to the blinding of personnel, participants and outcome assessors. </p> <p>We decided to perform a post‐hoc sensitivity analysis, in which we removed studies that tested antibiotic regimens which are no longer in use because of low efficacy. Importantly, two of the three studies removed for this reason contributed considerable weight to the primary analysis: 24.7% (<a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a>), and 14.8% (<a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a>). </p> <p>In the next update of this review, we intend to perform an overall analysis including only studies that have tested recommended regimens on date, and a sensitivity analysis including all studies available, even if the regimens tested are outdated. </p> <p>We also decided to add a subgroup analysis for smoking status, as tobacco use could interfere in <i>H pylori</i> eradication rates. </p> <p>This review has some limitations, as follows.</p> <p> <ul id="CD012357-list-0021"> <li> <p>We found a lack of outcome data in the included RCTs, even after trying contact the correspondent authors via email. In some studies, authors removed participants from an analysis because of non‐compliance (even because of adverse effects), without stating which group they were allocated to. </p> </li> <li> <p>There weren't any comparisons with two or more studies testing the same antibiotic regimen, leading to consequent clinical heterogeneity. </p> </li> </ul> </p> </section> <section id="CD012357-sec-0131"> <h3 class="title" id="CD012357-sec-0131">Agreements and disagreements with other studies or reviews</h3> <p>At the end of reporting this review, there was no other review in progress or already published with a similar clinical question. </p> <p>Two ongoing studies are testing NAC for <i>H pylori</i> eradication: </p> <p> <ol id="CD012357-list-0022"> <li> <p>comparing the efficacy of standard triple therapy with or without NAC in the first line of <i>H pylori</i> infection (<a href="./references#CD012357-bbs2-0010" title="NCT02249546 . Efficacy of acetylcysteine‐containing triple therapy in the first line of Helicobacter pylori infection [Comparison of the efficacy of triple therapy with or without acetylcysteine in the first line of Helicobacter pylori infection ‐ a multicenter randomized comparative trial]. clinicaltrials.gov/ct2/show/NCT02249546 (first received 25 September 2014). ">NCT02249546</a>); and </p> </li> <li> <p>comparing efficacy and safety of 10‐day triple therapy (rabeprazole, clarithromycin, and amoxicillin) plus NAC versus 10‐day concomitant therapy (rabeprazole, clarithromycin, amoxicillin, and metronidazole) for re‐eradication <i>H pylori</i> infection (<a href="./references#CD012357-bbs2-0009" title="NCT01572597 . Increased re‐eradication rate of Helicobacter pylori by adding N‐acetylcysteine or metronidazole to the triple therapy [Increased second‐line eradication rate of Helicobacter pylori by adding N‐acetylcysteine or metronidazole to the conventional triple therapy]. clinicaltrials.gov/ct2/show/NCT01572597 (first received 6 April 2012). ">NCT01572597</a>). </p> </li> </ol> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012357-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012357-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012357-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD012357-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 1 Eradication rate." data-id="CD012357-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 1 Eradication rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#CD012357-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 2 Gastrointestinal adverse events." data-id="CD012357-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 2 Gastrointestinal adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#CD012357-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 3 Allergic adverse events." data-id="CD012357-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 3 Allergic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#CD012357-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 4 Toxic adverse events." data-id="CD012357-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 4 Toxic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#CD012357-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 5 Eradication according to smoking status." data-id="CD012357-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 5 Eradication according to smoking status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#CD012357-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 6 Eradication according to diagnostic test used to confirm it." data-id="CD012357-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 6 Eradication according to diagnostic test used to confirm it. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#CD012357-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012357-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/urn:x-wiley:14651858:media:CD012357:CD012357-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_t/tCD012357-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 7 Eradication according to currently used regimens." data-id="CD012357-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone, Outcome 7 Eradication according to currently used regimens. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#CD012357-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/media/CDSR/CD012357/image_n/nCD012357-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012357-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any antibiotic regimen plus N‐acetylcysteine compared to the same regimen without N‐acetylcysteine (with or without placebo) for Helicobacter pylori infection</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any antibiotic regimen plus NAC compared to the same regimen without NAC (with or without placebo) for <i>H pylori</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with<i>H pylori</i> infection<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> any antibiotic regimen plus NAC<br/> <b>Comparison:</b> the same antibiotic regimen (with or without placebo) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any antibiotic regimen without NAC</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any antibiotic regimen plus NAC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Eradication rate</b> </p> <p>Follow‐up: 38 to 175 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.74</b><br/> (0.51 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>559<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>491 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b><br/> (250 to 530) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Triple therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>483 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> <p>(203 to 440)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62</p> <p>(0.42 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Dual therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>702 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000</p> <p>(295 to 632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62</p> <p>(0.42 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Sequential therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>328 per 1000</p> <p>(193 to 546)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78</p> <p>(0.46 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Bismuth quadruple therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> <p>(84 to 383)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98</p> <p>(0.46 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>No PPI, antibiotic monotherapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>456 per 1000</p> <p>(264 to 788)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14</p> <p>(0.66 to 1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Gastrointestinal adverse events</b> </p> <p>Follow‐up: 38 to 175 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.25</b><br/> (0.85 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>336<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>189 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b><br/> (161 to 350) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Triple therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>399 per 1000</p> <p>(171 to 942)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.33</p> <p>(0.57 to 3.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(1RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Dual therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Sequential therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000</p> <p>(131 to 550)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02</p> <p>(0.50 to 2.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Bismuth quadruple therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>345 per 1000</p> <p>(198 to 603)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.38</p> <p>(0.79 to 2.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>No PPI, antibiotic monotherapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Allergic adverse events</b> </p> <p>Follow‐up: 38 to 175 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.98</b><br/> (0.32 to 27.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>336<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Triple therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Dual therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00</p> <p>(0.13 to 68.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Sequential therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in either group</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Bismuth quadruple therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.95</p> <p>(0.12 to 71.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>No PPI, antibiotic monotherapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Toxic adverse events</b> </p> <p>Follow‐up: 38 to 175 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>336<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events in either group</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Triple therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Dual Therapies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Sequential therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>Bismuth quadruple therapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><b><i>No PPI, antibiotic monotherapy</i> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>PPI:</b> proton pump inhibitor; <b>NAC:</b> N‐acetylcysteine; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> We downgraded by one level due to risk of bias (lack of information on sequence generation and allocation concealment). </p> <p><sup>2</sup> We downgraded by one level due to imprecision (the confidence interval includes both null effect and appreciable benefit (RR 0.75)). </p> <p><sup>3</sup> We downgraded by two levels due to inconsistency (large variation of effect, confidence intervals do not overlap, I<sup>2</sup> &gt; 50% and P &lt; 0.05). </p> <p><sup>4</sup> We downgraded by two levels due to risk of bias (lack of blinding of participants, personnel, and outcome assessors). </p> <p><sup>5</sup> We downgraded by two levels due to imprecision (wide confidence interval that includes appreciable harm (RR 1.25)). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any antibiotic regimen plus N‐acetylcysteine compared to the same regimen without N‐acetylcysteine (with or without placebo) for Helicobacter pylori infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012357-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control (no NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally twice daily plus amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily and clarithromycin 500 mg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, placebo controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0004" title="HamidianSMT , AletahaNS , TaslimiR , MontazeriM . An additive effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori . Journal of Pathogens2015;2015:540271. [DOI: 10.1155/2015/540271] ">Hamidian 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally twice daily plus amoxicillin 500 mg four times daily, bismuth citrate 120 mg four times daily, omeprazole 20 mg twice daily, and clarithromycin 500 mg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0002" title="EmamiMH , ZobeiriM , RahimiH , ArjomandiF , DaghagzadehH , AdibiP , et al. N‐acetyl cysteine as an adjunct to standard anti‐Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open‐label trial. Advanced Biomedical Research2014;3:189. ">Emami 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 400 mg orally twice daily plus sequential therapy with rabeprazole 20 mg and amoxicillin 1g (both twice daily) for the first five days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg (all drugs twice daily) for the remaining five days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0007" title="YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. Effects of N‐acetylcysteine on first‐line sequential therapy for Helicobacter pylori Infection: A randomized controlled pilot trial. Gut and Liver2016;10(4):520‐25. YoonH , LeeDH , JangES , KimJ , ShinCM , ParkYS , et al. The effects of N‐acetylcysteine on first‐line 10‐day sequential therapy for Helicobacter pylori infection: A randomized controlled trial. United European Gastroenterology Journal2014;2(1 Suppl 1):A4301. ">Yoon 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally twice daily plus ciprofloxacin 500 mg twice daily, pantoprazole 40 mg twice daily and bismuth subcitrate 120 mg two tablets twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, placebo controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0006" title="KarbasiA , HosseinHS , ShohratiM , AminiM , NajafianB . Effect of oral N‐acetyl cysteine on eradication of Helicobacter pylori in patients with dyspepsia. Minerva Gastroenterologica e Dietologica2013;59(1):107‐12. ">Karbasi 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally once a day for one week before a culture‐guided regimen, including a proton pump inhibitor (PPI) plus two antibiotics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0001" title="CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clinical Gastroenterology and Hepatology2010;8(9):817‐20.e3. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Histopathologic and morphologic evaluations of resistant strains of H. pylori, and consequent new therapeutic approaches: usefulness of N‐acetil‐cysteine and culture‐guided antibiotics. Helicobacter2009;14(4):334. CammarotaG , IaniroG , CazzatoA , PiscagliaAC , LauritanoC , GiganteG , et al. Pre‐treatment with N‐acetil‐cysteine and culture‐guided rescue therapy for eradication of Helicobacter pylori infection. Gastroenterology2009;136(5 Suppl 1):A345W. ">Cammarota 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 400 mg orally three times a day plus clarithromycin 500 mg twice daily and lansoprazole 30 mg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0003" title="GurbuzAK , OzelAM , OzturkR , YildirimS , YazganY , DemirturkL . Effect of N‐acetyl cysteine onHelicobacter pylori . Southern Medical Journal2005;98(11):1095‐7. ">Gurbuz 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally twice daily plus omeprazole 40 mg twice daily and amoxicillin 750 mg twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, without placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0008" title="ZalaG , FluryR , WustJ , MeyenbergerC , AmmannR , WirthHP . N‐acetylcysteine improves eradication of Helicobacter pylori by omeprazole/amoxicillin in cigarette smokers. Schweizerische Medizinische Wochenschrift1994;124(31‐32):1391‐7. ">Zala 1994</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC 600 mg orally three times a day plus amoxicillin 375 mg three times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same regimen, placebo controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012357-bbs2-0005" title="HansenIM , LarsenJF , QvistN , LundborgCJ , BrandslundI , AxelssonCK . N‐acetylcysteine does not enhance eradication of Helicobacter pylori by amoxycillin. European Journal of Clinical Research1994;5:185‐91. ">Hansen 1994</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>NAC: N‐acetylcysteine</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/full#CD012357-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012357-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Eradication rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Triple therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.42, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Dual therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.42, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Sequential therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.46, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Bismuth quadruple therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.46, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 No PPI, antibiotic monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.01, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Gastrointestinal adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.85, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Triple therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.57, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dual therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sequential therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.50, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Bismuth quadruple therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.79, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Allergic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [0.32, 27.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Triple therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dual therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Sequential therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Bismuth quadruple therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.12, 71.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Toxic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Triple therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Dual therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Sequential therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Bismuth quadruple therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Eradication according to smoking status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.40, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Non smokers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.33, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Smokers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.27, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Eradication according to diagnostic test used to confirm it <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Endoscopic procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.37, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Stool antigen test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.46, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Urea breath test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.49, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Eradication according to currently used regimens <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.53, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any antibiotic regimen plus N‐acetylcysteine versus the same antibiotic regimen alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012357.pub2/references#CD012357-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012357.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012357-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012357-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012357-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012357-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012357-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012357-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012357-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD012357-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012357-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012357-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012357\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012357\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012357\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012357\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012357\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012357.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012357.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012357.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012357.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012357.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726809374"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012357.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726809378"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012357.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9cb82ca8f480',t:'MTc0MDcyNjgwOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 